![]() The analysts expect a Ph3 study to be required for regulatory purposes, potentially with AndexXa as an active comparator versus ciraparantag. READ: Portola Pharmaceuticals has 3 'differentiated assets' with strong potential, says Oppenheimer Both studies have primary completion in July. ![]() It is in separate Ph2 studies for the reversal of Xarelto and Eliquis. Perosphere Pharmaceuticals Inc.’s Ciraparantag is the only potential competitor to AndexXa currently in clinical development. the NBI and S&P 500 both up 4% YTD), we explore one of the bear theses we consider potentially misleading,” wrote Oppenheimer analysts Jay Olson and Silvan Tuerkcan in a research note released Thursday. “With Portola shares down 16% YTD despite FDA approval of AndexXa on May 4 (vs. In May, AndexXa became the first and only antidote for life-threatening or uncontrolled bleeding in patients taking blood thinners made with rivaroxaban and apixaban. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.Īnalysts at Oppenheimer debunked the idea that there was any serious competitive threat to Portola Pharmaceuticals Inc.’s ( NASDAQ:PTLA) bleeding antidote AndexXa. Proactive will on occasion use automation and software tools, including generative AI. The team also has access to and use technologies to assist and enhance workflows. Our human content creators are equipped with many decades of valuable expertise and experience. Proactive has always been a forward looking and enthusiastic technology adopter. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. This is content that excites and engages motivated private investors. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. ![]() Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. She has also worked for Agency France Presse, Business Standard, and the Financial Times in London. Previously, as a senior writer for Forbes India based in New York she has interviewed Fortune 500 CEOs and reported on state visits to Washington from the White House. She has reported on markets, foreign policy, and business from North America, Asia, and Europe. The use of the antidote is increasing due to the safety and efficacy profile of rivaroxaban and apixaban compared with warfarin and enoxaparin to treat and prevent conditions such as pulmonary embolism, stroke and venous thromboembolism, according to the press release.Īs Cardiology Today previously reported, the antidote was approved by the FDA last year, which was based on results from the phase 3 ANNEXA studies.Uttara is the Business News Editor at Proactive and oversees the creation of feature articles and marquee CEO interviews. Portola Pharmaceuticals announced that the FDA approved its Prior Approval Supplement for the second generation of andexanet alfa, allowing for its broad commercial launch in the U.S.Īndexanet alfa (Andexxa, Portola) is an antidote for patients treated with rivaroxaban (Xarelto, Janssen) or apixaban (Eliquis, Bristol-Myers Squibb) who require anticoagulation reversal due to uncontrolled or life-threatening bleeding, according to a press release from the company. ![]() If you continue to have this issue please contact to Healio ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |